Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).
Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).
Luis M. Montuenga, PhD, of the University of Navarra, discusses the potential contributions of biomarkers, promising biomarker panels being tested and published, the need to standardize biospecimen collection, and how to improve the sensitivity of these biomarkers (Abstract PL05.06).
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of mesothelioma is on the rise; in the United Kingdom alone, it has gone up nearly 500% since the 1970s (Abstract PS01.11).
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and safety, with 37% of 51 evaluable patients exhibiting disease control (Abstract OA11.03).
